Compare PDM & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDM | PCRX |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1997 | 2010 |
| Metric | PDM | PCRX |
|---|---|---|
| Price | $8.23 | $25.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $9.00 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 1.2M | 458.9K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $564,994,000.00 | $541,533,000.00 |
| Revenue This Year | $4.21 | $6.78 |
| Revenue Next Year | $1.29 | $8.54 |
| P/E Ratio | ★ N/A | $346.71 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $6.32 | $18.80 |
| 52 Week High | $9.19 | $27.64 |
| Indicator | PDM | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.47 | 57.09 |
| Support Level | $8.03 | $20.27 |
| Resistance Level | $8.89 | $25.50 |
| Average True Range (ATR) | 0.25 | 1.15 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 81.51 | 52.36 |
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.